NEXTECH INVEST LTD
Q4 2021 Form 13-F
ZURICH
CIK 0001911010
· CRD 322629
· Exempt reporting adviser
$379.6M Reported Value Total
Exempt Reporting Adviser
nextechinvest.com
Source: Form ADV filed 2026-03-27
Reported value
$379.6M
Quarter over quarter
0.0%
Holdings
11
Top-10 concentration
98.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Marco Weibel
Chief Financial Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2021 13F record
Q4 2021 13F filing summary
| Period of report | December 31, 2021 |
|---|---|
| Filed | February 14, 2022 |
| Form | 13F-HR |
| Reported value | $379.6M |
| Positions | 11 |
| Change in reported value | First reported quarter |
| Top-10 concentration | 98.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q4 2024 13F
Filed Feb 14, 2025
|
15 | $616.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
15 | $712.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $594.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
12 | $630.8M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
11 | $536.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
14 | $330.0M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
13 | $294.2M |
|
Q1 2023 13F
Filed May 12, 2023
|
12 | $239.6M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
14 | $251.4M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
14 | $309.6M |
|
Q2 2022 13F
Filed Aug 1, 2022
|
14 | $296.5M |
|
Q1 2022 13F
Filed May 16, 2022
|
14 | $350.3M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
11 | $379.6M |
Top 11 holdings · Q4 2021
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | EQRX EQRX INC | $89.4M | 23.55% |
| 2 | RVMD REVOLUTION MEDICINES INC | $74.7M | 19.68% |
| 3 | KNTE KINNATE BIOPHARMA INC | $53.3M | 14.04% |
| 4 | TYRA TYRA BIOSCIENCES INC | $35.4M | 9.34% |
| 5 | PMVP PMV PHARMACEUTICALS INC | $32.0M | 8.43% |
| 6 | ARVN ARVINAS INC | $23.6M | 6.22% |
| 7 | KRON KRONOS BIO INC | $19.7M | 5.2% |
| 8 | CGEM CULLINAN ONCOLOGY INC | $18.8M | 4.96% |
| 9 | SPRY SILVERBACK THERAPEUTICS INC | $12.7M | 3.35% |
| 10 | CCCC C4 THERAPEUTICS INC | $12.1M | 3.19% |
| 11 | THRX THESEUS PHARMACEUTICALS INC | $7.8M | 2.04% |
Values as reported on the Q4 2021 Form 13F. Every position is in the holdings table below.